MedinCell signs new 40 million-euro loan agreement with EIB

25 November 2022

French pharma company MedinCell (EPA: MEDCL) has signed a new 40 million-euro ($41.6 million) loan agreement with the European Investment Bank (EIB), backed by the Investment Plan for Europe.

The financing is intended to support the development of the company’s portfolio of innovative treatments. MedinCell’s portfolio is already composed of several long-active injectable products at pre-clinical and clinical stage. A first product using MedinCell’s BEPO technology is expected to reach the US market in the first half of 2023.

The product is mdc-IRM, a risperidone subcutaneous long-acting injectable (LAI) for the maintenance treatment of schizophrenia. This has been licensed to Israel-based Teva Pharmaceutical Industries which, upon US regulatory approval, will market the drug under the trade name Uzedy. MedinCell is potentially eligible for development and commercial milestones (up to $122 million), and royalties on net sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK